Livzon Pharma profit surges 14% despite flat revenue

Livzon Pharmaceutical Group reported operating income of RMB6.27 billion for the six months ended June 30, down 0.17% year-on-year. However, total profit surged 13.66% to RMB1.83 billion.

The company received marketing approval for two new products - Aripiprazole microspheres for injection and Progesterone injection. Another key project, JP-1366 tablets, completed Phase III clinical trials and was submitted for marketing approval.

Overseas revenue grew 18.40% to approximately RMB1 billion, contributing 16% of total operating revenue.